The lawsuit, filed in the U.S. District Court for the Northern District of California, contends that PROCEPT executives misrepresented the relationship between handpiece sales and clinical procedures. While the company previously maintained that customers ordered products strictly as needed, the complaint alleges that a hidden discount strategy led to inventory levels far exceeding actual surgical usage. This discrepancy culminated in a series of downward stock adjustments throughout 2025 and early 2026.

The most severe market reaction occurred following the February 2026 fiscal results, which revealed a cumulative excess of 10,000 units in field inventory and a 30% contraction in U.S. sales. That disclosure triggered an 18% decline in share price over two days. Investors seeking to serve as lead plaintiff in the case, captioned Operating Engineers Construction Industry and Miscellaneous Pension Fund v. PROCEPT BioRobotics Corporation, have until September 22, 2026, to petition the court.